GBIL expects to introduce the genetic test to all Svenson Hair Centres in Hong Kong and Singapore. HairDX’s easy to use genetic test provides an understandable genetic analysis of a man’s or woman’s likelihood of developing Androgenetic Alopecia, the most common type of hair loss.

The HairDX test collection kit is listed with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and the FDA as a Class I medical device. It is also available as a CE Marked product under the European In Vitro Diagnostic Directive.

DermaGenoma said that its genetic tests are available through physician’s offices nationwide, and are administered using a simple cheek swab.

Benjamin Lo, CEO of Global Beauty International, said: “This test adds a vital new element to our professional diagnostic capabilities. At Svenson, we believe that only when the real cause of a client’s hair loss is determined can an effective tailor-made treatment program begin. HairDX helps us determine a genetic susceptibility to hair loss before thinning or receding hair becomes apparent.

“Anyone, male or female, worried about losing hair can come to Svenson for a simple, confidential predictive test. As a worldwide leader in the fight against hair loss, at the forefront of using the latest technology to enhance the accuracy of diagnosis and treatment efficacy, Svenson is delighted to bring HairDX to Hong Kong and Singapore.”

Andy Goren, CEO of DermaGenoma, parent company of HairDX, said: “We’re pleased to expand the HairDX global leadership to Hong Kong and Singapore through our partnership with Global Beauty International. It brings the latest in genetic science to men and women concerned about their susceptibility to hair loss.”

Headquartered in Irvine, DermaGenoma is a molecular dermatology company founded by researchers and specialists in genetics and dermatology. The company is dedicated to the research and development of new diagnostics and prescription based therapies for skin conditions tailored to an individual’s genetic makeup.